Investor Presentaiton

Next Wave New project: DS-1471 starts Ph1 study DS-1471 is a monoclonal antibody targeting CD147 Ph1 study for solid tumors is planned to start in FY2023 H2 Daiichi-Sankyo ITGA ITGB DS-1471 anti-CD147 antibody binding to target CD147 CD44 MCT Suppression of CD147 complex ITGA ITGB CD147 CD44 MCT ↑ Stress response ↑ SMAD ↑ JNK ↑ P38 Cell membrane Cell death ↑ Caspase3 ■CD147 complex is important in survival, such as invasion and metastasis, in cancer tissues; also involved in embryogenesis and wound healing etc., in normal tissue ■Unique MoA by downregulation of CD147 complex leading to cellular stress response and apoptotic cell death ■FIH study composed of dose escalation and dose expansion in solid tumors will start FY2023 H2 FIH: first in human, MoA: mechanism of action 27

View entire presentation